Immune-Onc Therapeutics, Inc. Announces $7 Million Series A Financing

Published: Sep 01, 2016

PALO ALTO, Calif., Sept. 1, 2016 /PRNewswire/ -- Immune-Onc Therapeutics, Inc. ("Immune-Onc"), a newly formed biopharmaceutical company focused on advancing promising immuno-oncology therapeutics, announced a Series A financing of $7 million. Major investors include Fame Mount Limited and CLI Ventures. The financing will support discovery and development of novel antibodies with breakthrough potential in the area of cancer immunotherapy.

Immune-Onc Therapeutics, Inc. Logo

"Immuno-oncology drugs are transforming cancer care worldwide.  We are grateful for the support of our Series A investors who share our vision to pursue novel therapeutic antibodies targeting the immune system and tumor microenvironment," said Charlene Liao, Ph.D., Chief Executive Officer of Immune-Onc. "Our immuno-oncology programs leverage the latest scientific insights to advance new treatment options for cancer patients."

Immune-Onc was co-founded by Charlene Liao, Ph.D., who serves as its President and CEO, and Guo-Liang Yu, Ph.D., a serial entrepreneur and industry veteran.  Dr. Liao was Project Team Leader at Genentech, a member of the Roche Group, where she spent nearly 14 years leading oncology and immunology drug development programs from preclinical to Phase 3.  Dr. Liao was a Fellow of the Damon Runyon Cancer Research Foundation and a Special Fellow of the Leukemia and Lymphoma Society. Dr. Yu was the co-founder and CEO of Epitomics Inc., an antibody company acquired by Abcam for $170 million.  He currently holds numerous board and management positions, including Executive Chairman of Crown Bioscience Inc., a leading oncology platform company, and Venture Partner of OrbiMed, a healthcare and life sciences-dedicated investment firm.

About Immune-Onc Therapeutics, Inc.

Immune-Onc Therapeutics, Inc. ("Immune-Onc") is a newly established biopharmaceutical company focused on developing innovative therapeutic antibodies for cancer treatment. The Company is applying the latest scientific insights and expertise in drug development to advance novelimmuno-oncology products and bring new treatment options to cancer patients.  The company was founded in 2016 with headquarters in Palo Alto, California.




To view the original version on PR Newswire, visit:

SOURCE Immune-Onc Therapeutics, Inc.

Back to news